Background: Serum levels of B cell activating factor (BAFF) rise following Rituximab (RTX) therapy in patients with Rheumatoid arthritis (RA). CD5+IgM+B cells are present within transitional and naïve B cell subsets and their increased production or accumulation is associated with some autoimmune diseases. Previous studies have shown that BAFF does not enhance their survival compared with CD5-naïve B cells, suggesting that signalling pathways are important in promoting their survival. Objectives: To determine serum BAFF levels and BAFF-receptor (BAFF-R) expression in CD5+IgM+B cells in healthy controls (HC), RTX-naïve RA patients (pre-RTX), and relapsing at different time points after peripheral B cell repopulation post-RTX treatment, divided into 2 groups: early relapsers (0-3 months post-B cell return) and later relapsers (>4 months post-B cell return). Methods: Immunophenotyping of peripheral blood mononuclear cells was used to determine %CD5+IgM+B cells and BAFF-R (% and expression, mean fluorescence intensity (MFI)) in 5 HC, 13 pre-RTX and 12 post-RTX RA patients. Results were analyzed with respect to timing of relapse after peripheral B cell return (≥5 B cells/μL) and serum BAFF levels. Results: %CD5+IgM+B cells, but not absolute numbers, were significantly higher in post-RTX early relapsers compared to HC (p<0.01), pre-RTX patients (p<0.001) and post-RTX later relapsers (p<0.01). There was a strong inverse correlation between %CD5+IgM+B cells and time after B cell return (r 2 =0.88, p<0.0001). BAFF-R+ expression was significantly lower in both post-RTX groups compared to HC and pre-RTX patients; early relapsers showed the lowest % and MFI BAFF-R+ expression, compared with later relapsers (p<0.01). BAFF-R+ expression increased with time after B cell return, both % (r 2 =0.47, p<0.002) and MFI (r 2 =0.76, p<0.0004). BAFF levels were significantly higher in both post-RTX groups compared to HC and pre-RTX patients, with the highest BAFF levels in early relapsers (p<0.05 compared to later relapsers). There was a significant inverse correlation between BAFF levels and % (r 2 =0.51, p<0.01) and MFI (r 2 =0.4, p<0.05) BAFF-R+ expression. Conclusions: Early relapsers show increased %CD5+IgM+ naïve B cells, and decreased BAFF-R expression, similar to ontogeny and what is seen in cord blood B cells. Whether the increased numbers of CD5+ naïve cells were contributing to relapse was not determined but they have the capacity to rapidly mature into autoantibody producing plasma cells, independent of the BAFF/BAFFR system. BAFF-R expression was found to increase with time after B cell return, again mirroring ontogeny with a later relapse showing more normalized BAFF/BAFF-R levels, suggesting their mechanism of relapse may follow a more conventional B cell differentiation pathway. Background: Monoclonal antibodies (mAb) have greatly facilitated the development of highly specific immunotherapy, with a significant improvement of clinical outcome in certain rheumatologic diseases. However, the approaching of many references licensed mAb (RLM) to the end of their licensing period, have stimulated a tremendous interest in the synthesis of a new generation of low-cost mAb referred to as biosimilars (BS) mAb (BSM), because of their similarity to the RLM. An essential requirement imposed by Regulatory Agencies for a mAb to be considered BS is that its variable region (VR) primary sequence must be highly similar to that of RLM. However, epitope recognition and affinity of a mAb very much depends on its VR conformational structure, which may differ even between two mAb bearing highly similar (but not identical) VR. The availability of reagents highly specific to the RLM VR may offer an unique opportunity to define whether a mAb can or cannot be considered BS to a given RLM. Objectives: To isolate and characterize phage clone-expressing peptide (pc) which are highly specific for the VR of two anti-TNF-α RLP namely mAb Infliximab (Inf) and Golimumab (Gol).
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Background: Monoclonal antibodies (mAb) have greatly facilitated the development of highly specific immunotherapy, with a significant improvement of clinical outcome in certain rheumatologic diseases. However, the approaching of many references licensed mAb (RLM) to the end of their licensing period, have stimulated a tremendous interest in the synthesis of a new generation of low-cost mAb referred to as biosimilars (BS) mAb (BSM), because of their similarity to the RLM. An essential requirement imposed by Regulatory Agencies for a mAb to be considered BS is that its variable region (VR) primary sequence must be highly similar to that of RLM. However, epitope recognition and affinity of a mAb very much depends on its VR conformational structure, which may differ even between two mAb bearing highly similar (but not identical) VR. The availability of reagents highly specific to the RLM VR may offer an unique opportunity to define whether a mAb can or cannot be considered BS to a given RLM. Objectives: To isolate and characterize phage clone-expressing peptide (pc) which are highly specific for the VR of two anti-TNF-α RLP namely mAb Infliximab (Inf) and Golimumab (Gol). Methods: Cross-inhibition ELISA on recombinant TNF-α (rTNF-α) was performed to define the spatial relationship among the epitopes detected by mAb. mAbspecific phage clones expressing peptide (pc) were obtained by the panning of a phage peptide display library with TNF-a specific mAb. Characterization of pc-specificity and of the spatial relationship between pc-and the TNF-a-binding site on the variable region of mAb was assessed by binding and inhibition assay. Results: mAb Inf and Gol specifically and dose-dependently cross-inhibited each to the other in the binding to rTNF-a, indicating the recognition by these 2 mAb of the same or two distinct spatially related epitopes on TNF-a. The panning of mAb Inf and Gol with a phage peptide display library resulted in the isolation of one Inf-specific pc (pcInf) and three Gol-specific pc (pcGol1 to 3). Binding assay showed that pcInf and the three pcGol specifically reacted with the corresponding mAb. Furthermore, pcInf and pcGol3 specifically and dose-dependently inhibited the binding of the corresponding mAb to rTNF-α, suggesting the recognition by the pc of the corresponding mAb antigen-combining site. Finally, pcInf and all three pcGol did not react with two additional TNF-a antagonists, suggesting that they are highly specific for mAb Inf and Gol respectively.
Conclusions:
The highly specificity of the pc described indicates that they can be eventually employed to predict similarity between a newly synthesized BSM and the claimed RLM, based on the BSM reactivity (or the lack of reactivity) with RLM-specific pc. Background: The management of the chronic inflammatory rheumatisms has dramatically evolved in the last decade with a concept of "treat to target". The theory of a window of opportunity with more beneficial effects of an early intensive treatment is supported by several evidences. The positive impact of an early treatment with a TNFα blocker is expected but the place and the interest of non-steroidal anti-inflammatory treatments (NSAIDs) and glucocorticoids is not clear. Objectives: The aim of this study was to evaluate the radiological outcomes after an early treatment during 21 days by Etanercept, or Naproxene, or Celecoxib, or Prednisone, or Diclofenac or Methotrexate in adjuvant induced arthritis in rats. Methods: Adjuvant-induced arthritis (AIA) was induced in 6 weeks old male Lewis rats by injection of Mycobacterium butyricum in adjuvant at the basis of the tail. At the onset of arthritis, rats were daily treated with Naproxene (10 mg/kg/d i.p), or Diclofenac (5mg/kg i.p twice a day), or Celecoxib (3 mg/kg/d i.p) or Prednisone (10 mg/kg/d i.p), or Etanercept (10 mg/kg/3 days, s.c.), or Methotrexate (1mg/kg/3 days, s.c.), or saline solution (Vehicle), for 21 days. Arthritic score was daily monitored. At the end of treatment, paws' radiological exam was performed with a BMA High Resolution Digital X Ray (40mV, 10mA). A score of 0 to 20 was determined for each paw using a grading scale modified from Ackerman et al (1979) .
